Insider · CIK 0001295830
Alan A Musso
Files at RNTX (Rein Therapeutics, Inc.), FULC (Fulcrum Therapeutics, Inc.). First filing -, latest -.
In brief
Alan A Musso files SEC Form 4 as director and CFO at RNTX (Rein Therapeutics, Inc.), and also at FULC (Fulcrum Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Alan A Musso has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | FULC Fulcrum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +170,000 | $0.00 | $0 | 170,000 | Feb 4, 2026 |
| Jul 23, 2025 | RNTX Rein Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jul 23, 2025 |
| Jan 24, 2025 | FULC Fulcrum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +285,000 | $0.00 | $0 | 285,000 | Jan 28, 2025 |
| Dec 2, 2024 | RNTX Rein Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Dec 6, 2024 |
Questions about Alan A Musso
Answered from the filings on this page, as of the latest one.
Is Alan A Musso buying or selling?
Alan A Musso has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Alan A Musso's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alan A Musso has 0.
Where does Alan A Musso file Form 4?
Alan A Musso has filed Form 4 at RNTX (Rein Therapeutics, Inc.); FULC (Fulcrum Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.